The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot study of adjuvant chemotherapy with cisplatin and irinotecan for high-grade pulmonary neuroendocrine carcinona (large cell neuroendocrine carcinoma and small cell lung cancer).
H. Kenmotsu
No relevant relationships to disclose
S. Niho
No relevant relationships to disclose
T. Ito
No relevant relationships to disclose
Y. Ishikawa
No relevant relationships to disclose
H. Tada
No relevant relationships to disclose
I. Sekine
No relevant relationships to disclose
S. Watanabe
No relevant relationships to disclose
M. Yoshimura
No relevant relationships to disclose
N. Yamamoto
No relevant relationships to disclose
F. Oshita
No relevant relationships to disclose
K. Kubota
No relevant relationships to disclose
K. Nagai
No relevant relationships to disclose